One Pivotal Trial for FDA Approval? Success Depends on Trial Design
One pivotal trial for FDA approval could accelerate drug development, reshape clinical trial strategy, and change the pharmaceutical regulatory landscape.
The U.S. Food and Drug Administration (FDA) has quietly announced one of the most significant changes to clinical development policy.
Rather than expecting two clinical trials as the default standard for marketing approval, the FDA now intends to accept one adequate and well-controlled pivotal trial, supported by confirmatory evidence, for approval in many situations.
From Two Trials to One: Why the FDA Is Changing Course
The proposal announced in a research paper by an FDA Sounding Board does not lower the evidentiary bar for clinical study approval submissions.
Instead, it shifts the focus from the number of studies to the quality, credibility, and totality of evidence supporting a new medicine. For pharmaceutical developers, this could reshape clinical strategy, reduce development timelines, and accelerate patient access to innovative therapies.
For decades, many sponsors planned development programmes around two pivotal Phase III trials, even though U.S. law has allowed approval based on a single adequate and well-controlled study with confirmatory evidence since 1997.
That supporting evidence may include mechanistic science, real-world evidence, data from related indications, animal studies, or, where appropriate, a second clinical trial.
The FDA argues that today’s drug development landscape has changed too much and regulation needs to be modernised in response.
Advances in molecular biology, biomarker science, precision medicine, and translational research mean regulators can evaluate therapies using a broader evidence framework rather than relying solely on duplicate clinical studies.
The agency also notes that many oncology studies have already been supported by one pivotal trial for approval under existing regulatory flexibility.
Rather than treating two trials as the benchmark, the FDA intends to make one robust trial the default starting point while retaining the authority to require additional studies whenever scientific uncertainty remains.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
One Pivotal Trial for FDA Approval: Clinical Credibility Matters More Than Trial Numbers
One of the most important messages behind the policy is that clinical credibility cannot be measured simply by counting studies.
According to the FDA, confidence in a clinical programme depends on multiple interconnected factors, including:
- Robust randomised trial design
- Appropriate and contemporary control groups
- Clinically meaningful primary endpoints
- Strong biological plausibility
- Adequate statistical power
- Rigorous blinding and independent review
- Consistency between mechanistic and clinical evidence
-
High-quality statistical analysis plans
Image
A poorly designed programme does not become more reliable simply because it includes two studies.
Conversely, one exceptionally designed trial, supported by compelling clinical data, may provide stronger evidence of effectiveness than multiple weaker investigations.
This represents a subtle but important strategic shift. Sponsors may increasingly devote resources to designing one highly informative pivotal trial instead of dividing investment across multiple confirmatory studies.
The Looming Threat of Geopolitical Risk in Clinical Supply Chains
Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.
Faster Development Could Improve Pharmaceutical Innovation
The potential impact of this change to one pivotal trial for FDA approval will be substantial.
The FDA estimates that a single pivotal study can cost between US$30 million and US$150 million while adding years to development timelines.
Reducing unnecessary duplication could lower development costs, improve capital efficiency, and enable promising medicines to reach patients sooner.
Potential advantages include:
- Shorter development programmes
- Lower clinical trial costs
- Faster regulatory submissions
- Improved investment efficiency
- Earlier patient access to innovative therapies
For emerging biotechnology companies, reducing the number of pivotal studies may also improve financing prospects by lowering capital requirements before commercialisation.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
The New FDA Regulatory Standard Is Not One Size Fits All
The FDA is equally clear that one pivotal trial for approval will not become appropriate for every medicine.
Additional studies may still be required when:
- Mechanisms of action remain uncertain
- Surrogate endpoints provide limited confidence
- Clinical outcomes fluctuate substantially
- Trial limitations reduce confidence
- Biological evidence remains incomplete
In other words, flexibility does not replace clinical judgement. Instead, regulators intend to evaluate each programme according to its overall evidentiary strength rather than applying a fixed procedural requirement.
This places greater responsibility on sponsors during protocol development.
Trial design, endpoint selection, statistical methodology, and regulatory engagement may become even more important because the pivotal study carries greater weight throughout the review process.
Designing Decentralised Clinical Trials for Patient Diversity
Data shows that most DCT approaches significantly improve patient diversity. This analysis examines what the evidence means for clinical trial design strategy.
A New Era for Clinical Development Strategy and Drug Approvals
The FDA proposal for one study for regulatory market approval has already generated discussion across the pharmaceutical sector.
Supporters argue that it reflects advances in modern biomedical science and could encourage innovation without compromising regulatory standards. Others have questioned whether more empirical evidence should be presented to demonstrate that one well-designed trial consistently provides sufficient certainty across therapeutic areas.
Regardless of where the debate settles, sponsors should not interpret the policy as permission to do less in their clinical programmes.
Instead, sponsors should expect regulators to scrutinise pivotal studies even more closely. Protocol quality, endpoint selection, statistical rigour, and confirmatory evidence will become central determinants of regulatory success.
The future of FDA approval may depend less on conducting more trials and more on designing better ones.
At Pharmatica, we analyse the regulatory changes, clinical development strategies, and emerging technologies shaping the future of pharmaceutical innovation. Our independent Insights help life sciences leaders understand how evolving evidence standards influence drug development, regulatory planning, and commercial strategy.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is the FDA's one pivotal trial policy?
The FDA's new default policy allows many new medicines to be approved based on one adequate and well-controlled pivotal clinical trial supported by confirmatory evidence, rather than routinely requiring two pivotal studies.
What counts as confirmatory evidence for FDA approval?
Confirmatory evidence may include mechanistic data, real-world evidence, animal studies, biomarker evidence, data from related indications, or other scientific evidence that strengthens confidence in a therapy's effectiveness.
Will the FDA still require two pivotal clinical trials?
Yes. The FDA can still require two or more pivotal studies when scientific uncertainty remains, when mechanisms of action are unclear, when surrogate endpoints are used, or when trial limitations reduce confidence in the results.
How could one pivotal trial affect pharmaceutical companies?
A one pivotal trial approach could reduce development costs, shorten clinical timelines, improve capital efficiency, and enable innovative medicines to reach patients more quickly, provided the supporting evidence is sufficiently robust.
Does one pivotal trial lower FDA approval standards?
No. The FDA has emphasised that the policy focuses on the quality and credibility of the total evidence package rather than simply reducing the number of clinical trials. Sponsors should expect greater scrutiny of trial design, endpoints, statistical methods, and confirmatory evidence.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)